JP4707832B2 - 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド - Google Patents

髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド Download PDF

Info

Publication number
JP4707832B2
JP4707832B2 JP2000548474A JP2000548474A JP4707832B2 JP 4707832 B2 JP4707832 B2 JP 4707832B2 JP 2000548474 A JP2000548474 A JP 2000548474A JP 2000548474 A JP2000548474 A JP 2000548474A JP 4707832 B2 JP4707832 B2 JP 4707832B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
polynucleotide
immunogenic fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000548474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514424A (ja
Inventor
ルーリー，ジーン−ルイス
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10831992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4707832(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2002514424A publication Critical patent/JP2002514424A/ja
Application granted granted Critical
Publication of JP4707832B2 publication Critical patent/JP4707832B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
JP2000548474A 1998-05-13 1999-05-07 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド Expired - Fee Related JP4707832B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9810276.7 1998-05-13
GBGB9810276.7A GB9810276D0 (en) 1998-05-13 1998-05-13 Novel compounds
PCT/EP1999/003255 WO1999058683A2 (en) 1998-05-13 1999-05-07 BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010044336A Division JP2010166921A (ja) 1998-05-13 2010-03-01 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド

Publications (2)

Publication Number Publication Date
JP2002514424A JP2002514424A (ja) 2002-05-21
JP4707832B2 true JP4707832B2 (ja) 2011-06-22

Family

ID=10831992

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000548474A Expired - Fee Related JP4707832B2 (ja) 1998-05-13 1999-05-07 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド
JP2010044336A Pending JP2010166921A (ja) 1998-05-13 2010-03-01 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010044336A Pending JP2010166921A (ja) 1998-05-13 2010-03-01 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド

Country Status (23)

Country Link
US (3) US6780419B1 (enExample)
EP (2) EP1078063B1 (enExample)
JP (2) JP4707832B2 (enExample)
KR (4) KR20100019461A (enExample)
CN (1) CN1322127C (enExample)
AT (1) ATE311457T1 (enExample)
AU (1) AU750032B2 (enExample)
BR (1) BR9910396A (enExample)
CA (1) CA2328403C (enExample)
CY (1) CY1105676T1 (enExample)
CZ (1) CZ299612B6 (enExample)
DE (1) DE69928658T2 (enExample)
DK (1) DK1078063T3 (enExample)
ES (1) ES2252946T3 (enExample)
GB (1) GB9810276D0 (enExample)
HU (1) HUP0102479A3 (enExample)
IL (2) IL139613A0 (enExample)
NO (2) NO326994B1 (enExample)
NZ (1) NZ508323A (enExample)
PL (1) PL197449B1 (enExample)
TR (1) TR200003347T2 (enExample)
WO (1) WO1999058683A2 (enExample)
ZA (1) ZA200006523B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
ATE446368T1 (de) † 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
AU2818101A (en) * 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
US7459930B2 (en) * 2006-11-14 2008-12-02 Micron Technology, Inc. Digital calibration circuits, devices and systems including same, and methods of operation
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0916570D0 (en) 2009-09-21 2009-10-28 Royal Holloway & Bedford New C Method
CA2792691A1 (en) 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example, neisserial, infection or disease
JP6316755B2 (ja) * 2012-01-05 2018-04-25 ドイチェス クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｉｄｈ１ｒ１３２ｈ変異陽性がんを治療または診断する手段および方法
PL3491441T3 (pl) 2016-07-27 2020-10-05 Prysmian S.P.A. Giętka taśma światłowodowa

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769240A (en) * 1980-09-15 1988-09-06 Bactex, Inc. Pili of neisseria and vaccine compositions containing same
US4702911A (en) * 1985-09-27 1987-10-27 Immunomed Corporation Preparation of bacterium pili subunits and vaccines containing pili subunits
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
FR2682041B1 (fr) * 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US5646259A (en) * 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
NZ571167A (en) * 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents

Also Published As

Publication number Publication date
CN1322127C (zh) 2007-06-20
ZA200006523B (en) 2001-11-12
IL139613A (en) 2014-03-31
KR20100019461A (ko) 2010-02-18
KR20080070073A (ko) 2008-07-29
NO20005696L (no) 2001-01-11
PL197449B1 (pl) 2008-03-31
JP2002514424A (ja) 2002-05-21
CN1309707A (zh) 2001-08-22
NO326994B1 (no) 2009-03-30
CA2328403C (en) 2013-11-05
GB9810276D0 (en) 1998-07-15
US6780419B1 (en) 2004-08-24
EP1078063B1 (en) 2005-11-30
EP1621623A2 (en) 2006-02-01
NZ508323A (en) 2002-10-25
KR20010043571A (ko) 2001-05-25
BR9910396A (pt) 2001-10-30
TR200003347T2 (tr) 2001-06-21
ATE311457T1 (de) 2005-12-15
PL345281A1 (en) 2001-12-03
WO1999058683A3 (en) 2000-04-06
AU4142099A (en) 1999-11-29
KR100897951B1 (ko) 2009-05-18
DK1078063T3 (da) 2006-04-03
JP2010166921A (ja) 2010-08-05
HK1036300A1 (en) 2001-12-28
NO20090955L (no) 2001-01-11
IL139613A0 (en) 2002-02-10
NO20005696D0 (no) 2000-11-10
AU750032B2 (en) 2002-07-11
CZ299612B6 (cs) 2008-09-17
HUP0102479A2 (hu) 2001-10-28
US20040265332A1 (en) 2004-12-30
DE69928658D1 (de) 2006-01-05
EP1078063A2 (en) 2001-02-28
KR20060076789A (ko) 2006-07-04
CZ20004202A3 (en) 2001-05-16
HUP0102479A3 (en) 2004-10-28
EP1621623A3 (en) 2009-02-18
WO1999058683A9 (en) 2002-05-02
CA2328403A1 (en) 1999-11-18
ES2252946T3 (es) 2006-05-16
WO1999058683A2 (en) 1999-11-18
CY1105676T1 (el) 2010-12-22
US20090093622A1 (en) 2009-04-09
DE69928658T2 (de) 2006-06-14
KR100673674B1 (ko) 2007-01-23

Similar Documents

Publication Publication Date Title
JP2010166921A (ja) 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド
JP2010166920A (ja) 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド
US20040132983A1 (en) BASB013 DNA and proteins from neisseria meningitidis
EP1080198B1 (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
EP1112366B1 (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
HK1036300B (en) Basb029 polynucleotides and polypeptides from neisseria meningitis
HK1091861A (en) Basb029 polynucleotide(s) and polypeptides from neisseria meningitis
HK1160490A (en) Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
HK1038041B (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101224

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110316

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees